MA33903B1 - Antagonistes de pcsk9 - Google Patents

Antagonistes de pcsk9

Info

Publication number
MA33903B1
MA33903B1 MA35037A MA35037A MA33903B1 MA 33903 B1 MA33903 B1 MA 33903B1 MA 35037 A MA35037 A MA 35037A MA 35037 A MA35037 A MA 35037A MA 33903 B1 MA33903 B1 MA 33903B1
Authority
MA
Morocco
Prior art keywords
pcsk9
antagonists
antibodies
methods
relates
Prior art date
Application number
MA35037A
Other languages
Arabic (ar)
English (en)
Inventor
Sarah Rue
Steven B Cohen
Jun Li
David Yowe
Original Assignee
Irm Llc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43466865&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33903(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc, Novartis Ag filed Critical Irm Llc
Publication of MA33903B1 publication Critical patent/MA33903B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des antagonistes anticorps contre la proprotéine convertase subtilisine/kexine de type 9a (« PCSK9 ») et des procédés d'utilisation de tels anticorps.
MA35037A 2009-12-11 2010-12-10 Antagonistes de pcsk9 MA33903B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28594209P 2009-12-11 2009-12-11
PCT/US2010/059959 WO2011072263A1 (fr) 2009-12-11 2010-12-10 Antagonistes de pcsk9

Publications (1)

Publication Number Publication Date
MA33903B1 true MA33903B1 (fr) 2013-01-02

Family

ID=43466865

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35037A MA33903B1 (fr) 2009-12-11 2010-12-10 Antagonistes de pcsk9

Country Status (32)

Country Link
US (1) US8710192B2 (fr)
EP (1) EP2510013B1 (fr)
JP (2) JP5981347B2 (fr)
KR (1) KR101915496B1 (fr)
CN (1) CN102652139B (fr)
AR (1) AR079336A1 (fr)
AU (1) AU2010327924B2 (fr)
BR (1) BR112012013782A8 (fr)
CA (1) CA2781050C (fr)
CL (1) CL2012001529A1 (fr)
CO (1) CO6571886A2 (fr)
CR (1) CR20120371A (fr)
CU (1) CU24058B1 (fr)
EA (1) EA032084B1 (fr)
EC (1) ECSP12012034A (fr)
ES (1) ES2726040T3 (fr)
GT (1) GT201200189A (fr)
HN (1) HN2012001223A (fr)
IL (1) IL220091A0 (fr)
IN (1) IN2012DN05237A (fr)
MA (1) MA33903B1 (fr)
MX (1) MX2012006648A (fr)
NZ (2) NZ625433A (fr)
PE (1) PE20121361A1 (fr)
PH (1) PH12012501148A1 (fr)
PL (1) PL2510013T3 (fr)
PT (1) PT2510013T (fr)
TN (1) TN2012000243A1 (fr)
TR (1) TR201906696T4 (fr)
TW (1) TWI523662B (fr)
UY (1) UY33102A (fr)
WO (1) WO2011072263A1 (fr)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
CN110711248A (zh) 2011-01-28 2020-01-21 赛诺菲生物技术公司 包含针对pcsk9的人抗体的药物组合物
US20140004142A1 (en) * 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
AR088782A1 (es) * 2011-04-29 2014-07-10 Sanofi Sa Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
WO2012170607A2 (fr) * 2011-06-10 2012-12-13 Novartis Ag Utilisation d'antagonistes de pcsk9
WO2012168491A1 (fr) 2011-06-10 2012-12-13 Novartis Ag Formulations pharmaceutiques d'antagonistes de pcsk9
MX2014000578A (es) * 2011-07-14 2014-04-30 Pfizer Tratamiento con anticuerpos anti-pcsk9.
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2992345T3 (es) 2011-09-16 2024-12-11 Regeneron Pharma Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
AR087715A1 (es) * 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
TW201329104A (zh) 2011-12-08 2013-07-16 Amgen Inc 人類ｌｃａｔ抗原結合蛋白質及其治療用途
US9879093B2 (en) 2011-12-20 2018-01-30 Adaerata, Limited Partnershp Single domain antibodies as inhibitors of PCSK9
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US9266961B2 (en) * 2012-06-15 2016-02-23 Genentech, Inc. Anti-PCSK9 antibodies, formulations, dosing, and methods of use
AU2013302925B2 (en) 2012-08-13 2018-07-05 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
EP2703009A1 (fr) * 2012-08-31 2014-03-05 Sanofi Traitements combinés impliquant des anticorps de la PCSK9 humaine
EP2706070A1 (fr) * 2012-09-06 2014-03-12 Sanofi Traitements combinés impliquant des anticorps de la PCSK9 humaine
US12115341B2 (en) 2012-11-21 2024-10-15 Amgen Inc. Drug delivery device
US10287317B2 (en) * 2013-02-15 2019-05-14 Srx Cardio, Llc Proprotein convertase subtilisin kexin type 9 (PCSK9) allosteric binding ligands to modulate serum low density lipoprotein (LDL) levels
AU2014228177B2 (en) 2013-03-15 2018-04-26 Amgen Inc. Body contour adaptable autoinjector device
CA2904661C (fr) 2013-03-15 2022-03-15 Amgen Inc. Boite a medicament, autoinjecteur et systeme d'autoinjecteur
EP2968760B1 (fr) 2013-03-15 2024-01-03 Amgen Inc. Cartouche à médicament, auto-injecteur et système d'auto-injection
IL292270B2 (en) 2013-03-22 2024-04-01 Amgen Inc Injector and method of assembly
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI682780B (zh) * 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
EP2862877A1 (fr) 2013-10-18 2015-04-22 Sanofi Procédés pour inhiber l'athérosclérose par l'administration d'un inhibiteur de PCSK9
AU2014274844B2 (en) * 2013-06-07 2019-11-28 Regeneron Pharmaceuticals, Inc. Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
US20150004174A1 (en) * 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
MX2016005315A (es) 2013-10-24 2016-08-11 Amgen Inc Sistema de administracion de farmacos con control sensible a la temperatura.
SG11201602876WA (en) 2013-10-24 2016-05-30 Amgen Inc Injector and method of assembly
EP3068803B1 (fr) 2013-11-12 2021-01-20 Sanofi Biotechnology Schémas posologiques pour l'utlisation d' inhibiteurs de la pcsk9
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
FR3014695A1 (fr) * 2013-12-17 2015-06-19 Kymab Ltd
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
WO2015119906A1 (fr) 2014-02-05 2015-08-13 Amgen Inc. Système d'administration de médicament doté d'un générateur de champ électromagnétique
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102496507B1 (ko) 2014-05-07 2023-02-03 암겐 인코포레이티드 충격 감소 요소들을 가진 자동 주사기
KR20220143782A (ko) 2014-06-03 2022-10-25 암겐 인코포레이티드 약물 전달 디바이스의 사용자를 보조하기 위한 디바이스들 및 방법들
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
EP4328245A3 (fr) 2014-07-15 2024-06-05 Kymab Ltd. Anticorps utilisés dans le traitement de pathologies associées à des variants pcsk9 spécifiques dans des populations de patients spécifiques
DE202015009006U1 (de) 2014-07-15 2016-08-19 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
EP2975059A1 (fr) 2014-07-15 2016-01-20 Kymab Limited Anticorps pour utilisation dans le traitement de maladies liées à certains variants spécifiques de pcsk9 dans certaines populations spécifiques de patients
RU2735521C2 (ru) 2014-07-16 2020-11-03 Санофи Байотекнолоджи Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh)
WO2016023916A1 (fr) 2014-08-12 2016-02-18 Kymab Limited Traitement de maladie par la liaison d'un ligand à des cibles présentant un intérêt
US10472424B2 (en) * 2014-09-23 2019-11-12 Pfizer Inc. Treatment with anti-PCSK9 antibodies
MX2021014323A (es) 2014-10-14 2023-02-02 Amgen Inc Dispositivo de inyección de fármaco con indicadores visuales y audibles.
WO2016071701A1 (fr) 2014-11-07 2016-05-12 Kymab Limited Traitement de maladie par liaison de ligand à des cibles d'intérêt
EP3848072A1 (fr) 2014-12-19 2021-07-14 Amgen Inc. Dispositif d'administration de médicament comportant un capteur de proximité
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
CA3069716C (fr) 2015-02-17 2021-11-09 Amgen Inc. Dispositif d'administration de medicament a securisation assistee par depression et/ou retour d'informations
US11806509B2 (en) 2015-02-27 2023-11-07 Amgen Inc. Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
JP6869894B2 (ja) * 2015-03-20 2021-05-12 オーフス ウニベルシテット リポタンパク質代謝障害の治療のためのｐｃｓｋ９阻害剤
CN106084058B (zh) * 2015-07-15 2019-08-27 北京天广实生物技术股份有限公司 抗人pcsk9单克隆抗体
US10772956B2 (en) 2015-08-18 2020-09-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
WO2017039786A1 (fr) 2015-09-02 2017-03-09 Amgen Inc. Adaptateur d'ensemble de seringue pour une seringue
EP3386573B1 (fr) 2015-12-09 2019-10-02 Amgen Inc. Auto-injecteur avec capuchon de signalisation
US10793643B2 (en) 2015-12-31 2020-10-06 Jiangsu Hengrui Medicine Co., Ltd. PCSK9 antibody, antigen-binding fragment thereof, and medical application thereof
US20200270365A1 (en) 2016-01-05 2020-08-27 Jiangsu Hengrui Medicine Co., Ltd. Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereof
WO2017120178A1 (fr) 2016-01-06 2017-07-13 Amgen Inc. Auto-injecteur pourvu d'une électronique de signalisation
DK3429663T3 (da) 2016-03-15 2020-09-28 Amgen Inc Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
CN105801701B (zh) * 2016-03-31 2019-03-29 河北仁博科技有限公司 一种pcsk9抗体的重链和轻链可变区及其应用
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
WO2017197222A1 (fr) 2016-05-13 2017-11-16 Amgen Inc. Ensemble manchon de flacon
WO2017200989A1 (fr) 2016-05-16 2017-11-23 Amgen Inc. Chiffrement de données dans des dispositifs médicaux à capacité de calcul limitée
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2017220989A1 (fr) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 et cytokines il-2
WO2018004842A1 (fr) 2016-07-01 2018-01-04 Amgen Inc. Dispositif d'administration de médicament présentant un risque réduit au minimum de fracture de composant lors d'événements d'impact
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
EP3532127A1 (fr) 2016-10-25 2019-09-04 Amgen Inc. Injecteur porté sur le corps
EP3534947A1 (fr) 2016-11-03 2019-09-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
JOP20190112A1 (ar) 2016-11-14 2019-05-14 Amgen Inc علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
JP2020503976A (ja) 2017-01-17 2020-02-06 アムジエン・インコーポレーテツド 注入デバイスならびに関連する使用および組立方法
CA3048520A1 (fr) 2017-02-17 2018-08-23 Amgen Inc. Dispositif d'administration de medicament a trajet d'ecoulement de fluide sterile et procede d'assemblage associe
EP3582829A1 (fr) 2017-02-17 2019-12-25 Amgen Inc. Mécanisme d'insertion pour dispositif d'administration de médicament
JP2020508803A (ja) 2017-03-06 2020-03-26 アムジエン・インコーポレーテツド 作動防止特徴部を備える薬物送達デバイス
US11571511B2 (en) 2017-03-07 2023-02-07 Amgen Inc. Insertion mechanism and method of inserting a needle of a drug delivery device
KR102893480B1 (ko) 2017-03-09 2025-11-28 암겐 인코포레이티드 약물 전달 장치용 삽입 메커니즘
HUE063805T2 (hu) 2017-03-28 2024-01-28 Amgen Inc Dugattyúrúd és fecskendõ összeállító rendszer és eljárás
EP3609532A1 (fr) 2017-04-13 2020-02-19 Cadila Healthcare Limited Vaccin pcsk9 à base de nouveaux peptides
AU2018282077B2 (en) 2017-06-08 2023-11-23 Amgen Inc. Torque driven drug delivery device
CA3061982A1 (fr) 2017-06-08 2018-12-13 Amgen Inc. Ensemble de seringue d'un appareil d'administration de medicament et procede d'assemblage
MA49447A (fr) 2017-06-22 2020-04-29 Amgen Inc Réduction des impacts/chocs d'activation d'un dispositif
WO2018237225A1 (fr) 2017-06-23 2018-12-27 Amgen Inc. Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
MA49626A (fr) 2017-07-21 2020-05-27 Amgen Inc Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
JP2020528296A (ja) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
WO2019022950A1 (fr) 2017-07-25 2019-01-31 Amgen Inc. Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
US11077246B2 (en) 2017-08-18 2021-08-03 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
ES2939292T3 (es) 2017-10-04 2023-04-20 Amgen Inc Adaptador de flujo para dispositivo de administración de fármacos
EP3691716B1 (fr) 2017-10-06 2023-11-29 Amgen Inc. Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé
US11464903B2 (en) 2017-10-09 2022-10-11 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
WO2019090079A1 (fr) 2017-11-03 2019-05-09 Amgen Inc. Système et approches pour stériliser un dispositif d'administration de médicament
JP2021501616A (ja) 2017-11-06 2021-01-21 アムジエン・インコーポレーテツド 配置及び流量検出を備える薬物送達デバイス
US12053618B2 (en) 2017-11-06 2024-08-06 Amgen Inc. Fill-finish assemblies and related methods
MA50557A (fr) 2017-11-10 2020-09-16 Amgen Inc Pistons pour dispositifs d'administration de médicament
IL273638B2 (en) 2017-11-16 2024-10-01 Amgen Inc Door latch mechanism for drug delivery device
WO2019099322A1 (fr) 2017-11-16 2019-05-23 Amgen Inc. Auto-injecteur avec détection de décrochage et de point d'extrémité
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023220A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs d'administration de médicament hybrides dotés d'une partie de fixation collante à placer sur la peau et procédé de préparation associé
MA53379A (fr) 2018-07-24 2021-06-02 Amgen Inc Dispositifs d'administration pour l'administration de médicaments
WO2020023336A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs hybrides d'administration de médicament dotés d'une partie de préhension
CA3103682A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs d'administration pour l'administration de medicaments
MA53320A (fr) 2018-07-31 2021-11-03 Amgen Inc Ensemble de trajet de fluide pour dispositif d'administration de médicament
AU2019347710B2 (en) 2018-09-24 2025-05-08 Amgen Inc. Interventional dosing systems and methods
IL281469B2 (en) 2018-09-28 2024-08-01 Amgen Inc Muscle wire escapement activation assembly for a drug delivery device
US20200101016A1 (en) * 2018-10-02 2020-04-02 Exosome Therapeutics, Inc. Compositions and methods for producing exosome loaded therapeutics for treating cardiovascular disease
US12156991B2 (en) 2018-10-02 2024-12-03 Amgen Inc. Injection systems for drug delivery with internal force transmission
WO2020072846A1 (fr) 2018-10-05 2020-04-09 Amgen Inc. Dispositif d'administration de médicament ayant un indicateur de dose
WO2020081480A1 (fr) 2018-10-15 2020-04-23 Amgen Inc. Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament
US12053617B2 (en) 2018-10-15 2024-08-06 Amgen Inc. Drug delivery device having damping mechanism
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
US12485219B2 (en) 2018-11-01 2025-12-02 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
EP4470609A3 (fr) 2019-01-18 2025-03-12 Astrazeneca AB Inhibiteurs de pcsk9 et leurs procédés d'utilisation
ES3032751T3 (en) 2019-04-24 2025-07-24 Amgen Inc Syringe sterilization verification assemblies and methods
MX2021014015A (es) 2019-05-17 2022-02-21 Regeneron Pharma Metodos basados en el genoma para reducir el riesgo cardiovascular.
MX2022002149A (es) 2019-08-23 2022-03-17 Amgen Inc Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados.
KR20240011135A (ko) 2021-05-21 2024-01-25 암젠 인크 약물 용기를 위한 충전 레시피를 최적화하는 방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (fr) * 1974-06-07 1981-03-18
AU548996B2 (en) 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US20110230392A1 (en) * 1999-10-22 2011-09-22 Millennium Pharmaceuticals, Inc. Novel narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, and narc 25 molecules and uses therefor
WO2001057081A2 (fr) 2000-02-07 2001-08-09 Millennium Pharmaceuticals, Inc. Nouveaux homologues de type subtilase (narc-1)
AU2005207003C1 (en) * 2004-01-20 2013-06-13 Humanigen, Inc. Antibody specificity transfer using minimal essential binding determinants
AU2005306502B2 (en) * 2004-11-16 2012-11-15 Humanigen, Inc. Immunoglobulin variable region cassette exchange
US8211648B2 (en) 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
ES2366974T3 (es) * 2006-05-05 2011-10-27 Isis Pharmaceuticals, Inc. Compuestos y procedimientos para modular la expresión de sglt2.
KR101320916B1 (ko) * 2006-05-11 2013-10-23 알닐람 파마슈티칼스 인코포레이티드 Ｐｃｓｋ9 유전자의 발현을 억제하기 위한 조성물 및 방법
EP2083860A4 (fr) 2006-11-07 2010-05-26 Merck Sharp & Dohme Antagonistes de pcsk9
EP2083859A4 (fr) 2006-11-07 2010-11-24 Merck Sharp & Dohme Antagonistes de pcsk9
AU2007322265B2 (en) * 2006-11-07 2013-06-20 Merck Sharp & Dohme Corp. Antagonists of PCSK9
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
AR070316A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
EP2320772A1 (fr) 2008-07-25 2011-05-18 SPP Industries Holdings Pty Ltd Boîtier supérieur pour store
TWI445716B (zh) * 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).

Also Published As

Publication number Publication date
WO2011072263A1 (fr) 2011-06-16
CA2781050A1 (fr) 2011-06-16
AU2010327924B2 (en) 2014-09-04
MX2012006648A (es) 2013-05-30
TR201906696T4 (tr) 2019-05-21
IN2012DN05237A (fr) 2015-10-23
CN102652139B (zh) 2014-11-05
CO6571886A2 (es) 2012-11-30
AR079336A1 (es) 2012-01-18
US20110142849A1 (en) 2011-06-16
ES2726040T3 (es) 2019-10-01
AU2010327924A1 (en) 2012-07-05
JP2013513620A (ja) 2013-04-22
IL220091A0 (en) 2012-09-24
CU24058B1 (es) 2014-12-26
TWI523662B (zh) 2016-03-01
KR20120098873A (ko) 2012-09-05
JP5981347B2 (ja) 2016-08-31
CN102652139A (zh) 2012-08-29
ECSP12012034A (es) 2012-08-31
NZ601084A (en) 2014-06-27
CU20120095A7 (es) 2013-02-26
HN2012001223A (es) 2015-08-24
GT201200189A (es) 2014-06-06
PL2510013T3 (pl) 2019-08-30
KR101915496B1 (ko) 2018-11-08
UY33102A (es) 2011-07-29
EP2510013A1 (fr) 2012-10-17
US8710192B2 (en) 2014-04-29
BR112012013782A8 (pt) 2017-12-26
CR20120371A (es) 2016-07-20
EA201200861A1 (ru) 2013-01-30
EP2510013B1 (fr) 2019-02-13
CA2781050C (fr) 2019-06-11
JP6297088B2 (ja) 2018-03-20
PE20121361A1 (es) 2012-10-13
TN2012000243A1 (en) 2013-12-12
JP2016179979A (ja) 2016-10-13
NZ625433A (en) 2015-12-24
BR112012013782A2 (pt) 2017-01-10
CL2012001529A1 (es) 2012-08-03
PH12012501148A1 (en) 2017-02-03
PT2510013T (pt) 2019-05-30
EA032084B1 (ru) 2019-04-30
TW201136605A (en) 2011-11-01

Similar Documents

Publication Publication Date Title
MA33903B1 (fr) Antagonistes de pcsk9
MA34818B1 (fr) Anticorps anti-pcsk9 et procédés d'utilisation
EA201391157A1 (ru) Антагонисты pcsk9
MA34519B1 (fr) Anticorps anti-fap et procédés d'utilisation
EA202091373A1 (ru) Стабилизированные составы, содержащие антитела анти-pcsk9
IL273353B1 (en) Antigenic proteins that bind to proprotein convertase subtilisin kexin type 9 (pcsk9)
AU2014274844A8 (en) Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
WO2012170607A3 (fr) Utilisation d'antagonistes de pcsk9
MA34524B1 (fr) Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3)
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MA32535B1 (fr) Compositions et procédés pour des anticorps ciblant une protéine du complément c5
MA34488B1 (fr) Composition pesticides
MA30922B1 (fr) Anticorps d'agonistes de trkb et leurs utilisations
MA34541B1 (fr) Compositions d'anticorps et procédés d'utilisation
MA35807B1 (fr) Procedes de traitement ou de prevention de troubles associés au cholesterol